Evidence map›Paper›PMID 40366008›Full record

ArticleCancer medicine2025

NOP2-Mediated m5C Methylation Modification of LMNB2 mRNA Facilitates Colorectal Cancer Progression.

Jinling Bi, Yong Huang, Wentao Hu, Yulong Liu

Abstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. mBiology direct · 2026
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinling BiDepartment of Oncology, The Second People's Hospital of Hefei, Hefei, China.
Yong HuangDepartment of Oncology, The Second People's Hospital of Hefei, Hefei, China.
Wentao HuState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0001-8495-4175
Yulong LiuDepartment of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0003-2660-8076

Funding

National Natural Science Foundation of China 12475350National Natural Science Foundation of China U2267220Open Project of State Key Laboratory of Radiation Medicine and Protection GZK1202228
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality globally, yet current therapies exhibit suboptimal efficacy with limited prognostic improvement. RNA 5-methylcytosine (m5C), a posttranscriptional modification, has been implicated in tumorigenesis and progression across malignancies. In our previous study, the m5C methyltransferase NOP2 has been shown to promote proliferation, migration, and invasion of CRC cells, however, the underlying mechanism is still elusive.

methodsAn integrated multi-omics strategy was employed, combining transcriptomic sequencing, RNA immunoprecipitation sequencing (RIP-seq), and methylated RNA immunoprecipitation sequencing (MeRIP-seq) to explore NOP2-regulated downstream genes mediating CRC progression via m5C methylation. Functional validation included in vitro and in vivo assays to assess tumor growth and metastasis. Rescue experiments were performed by overexpressing LMNB2 in NOP2-silenced CRC cells.

resultsNOP2-dependent m5C modification of LMNB2 mRNA enhanced its stability, leading to elevated LMNB2 protein levels. This mechanism drove CRC tumor growth and metastasis both in vitro and in vivo. Overexpression of LMNB2 effectively rescued the suppressed malignant phenotypes induced by NOP2 knockdown, confirming LMNB2 as a critical downstream effector.

conclusionNOP2 catalyzes the m5C modification of LMNB2 mRNA to facilitate its stability, which contributes to the elevated LMNB2 protein level and CRC progression, suggesting the potential of NOP2 as a therapeutic target in the development of novel CRC treatment.

Indexed as

5-MethylcytosineColorectal NeoplasmsMethyltransferasesNuclear ProteinsRNA, MessengerAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHCT116 CellsHumansMethylationMiceMice, Nude5-MethylcytosineMethyltransferasesNuclear ProteinsRNA, Messengercolorectal cancerLMNB2m5CmethyltransferaseNOP2

Identifiers

PMID40366008
PMCPMC12076344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.